Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bromine-77-labeled prostate-specific membrane antigen ligand
- Development stage
- Preclinical
- Lead developer
- University of Michigan
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Bromine-77-labeled prostate-specific membrane antigen (PSMA) ligand is a radiolabeled small molecule targeting PSMA, developed for potential applications in targeted radionuclide therapy (specifically Auger-electron therapy) and SPECT imaging of prostate cancer. The agent utilizes the bromine-77 isotope (77Br), which decays via electron capture with a half-life of 57.0 hours, emitting low-energy Auger electrons that can induce highly localized, lethal double-strand DNA breaks when internalized into tumor cells. It is developed as part of an elementally matched theranostic pair alongside its positron-emitting counterpart, bromine-76 (76Br), which is used for PET imaging. Preclinical studies in murine tumor models have demonstrated favorable biodistribution and tumor-targeting capabilities concordant with established PSMA-targeting radioligands.
- Other names
- 77Br-PSMA ligand[77Br]Br-PSMA ligand[77Br]PSMA ligandbromine-77-labeled PSMA ligandbromine77-labeled PSMA ligandbromine 77-labeled PSMA ligand
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on bromine-77-labeled prostate-specific membrane antigen ligand.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bromine-77-labeled prostate-specific membrane antigen ligand.